| Literature DB >> 34336109 |
Alexandrina S Curpan1, Alina-Costina Luca2, Alin Ciobica3.
Abstract
Neurodevelopmental disorders are a category of diseases that is not yet fully understood. Due to their common traits and pathways, often it is difficult to differentiate between them based on their symptoms only. A series of hypotheses are trying to define their etiology, such as neuroinflammation, neurodegeneration, and immunology, but none have managed to explain their multifactorial manifestation. One feature that may link all theories is that of oxidative stress, with a redox imbalance as well as several other markers of oxidative damage (on lipids, proteins, and nucleic acids) being observed in both postmortem samples of the brain of patients with schizophrenia and autism spectrum disorders. However, the implication of oxidative stress in pathology is still distrustfully looked upon. For this purpose, in the current paper, we were interested in reviewing the implications of oxidative stress in these disorders as well as the impact of N-acetylcysteine on the oxidative status with a focus on the glutathione level and N-methyl-D-aspartate receptor. We were also interested in finding papers targeting the use of antioxidant properties of different plant extracts.Entities:
Mesh:
Year: 2021 PMID: 34336109 PMCID: PMC8321748 DOI: 10.1155/2021/6640206
Source DB: PubMed Journal: Oxid Med Cell Longev ISSN: 1942-0994 Impact factor: 6.543
Figure 1The division of the 73 articles selected based on the disorder (autism spectrum disorder (ASD), schizophrenia, and attention-deficit hyperactivity disorders (ADHD)) and +general aspects, +oxidative stress, +NMDAR (N-methyl-D-aspartate receptor/glutamate), +NAC (n-acetyl cysteine), and +phytochemicals.
Antioxidant properties of N-acetylcysteine in neurodevelopmental disorders.
| Authors | Model | Number of participants | Doses | Results |
|---|---|---|---|---|
| [ | Monkeys ( | 5 young males | (i) 150 mg/kg/h, i.v. over 30 min and 12 mg/kg/h, i.v. over 9 hours | (i) May attenuate the decrease in dopamine transporters after methamphetamine adm. |
| [ | Rats (western albino) | 28 young males divided into 4 groups (control, PPA treated, NAC → PPA (protective), PPA → NAC (therapeutic)) | 2–250 mg/kg/day PPA 3 d | (i) NAC successfully defied the oxidative stress induced by propionic acid administration |
| [ | Human | 150 | 1000 mg bidaily (6 months) | (i) Improved negative symptoms, but the improvements were lost 1 month after the end of the trial |
| [ | Human | 11 | 2000 mg/day (oral) (8 weeks) | (i) Significant improvements regarding mismatch negativity and plasma glutathione concentration |
| [ | Human | 1 female | 600 mg/day (oral)+usual medication | ↓ Positive and Negative Syndrome Scale (PANSS) |
| [ | Human | 63 (32 NAC, 31 placebo) | 2700 mg/day effervescent NAC (1800 mg in the morning, 900 evening, 6 months) | ↑ by 23% brain GSH levels in the medial prefrontal cortex |
| [ | Human | 33 (31 males, 2 females, ages 3.2-10.7 years) | 900 mg/day (4 weeks) → 900 mg/twice per day (4 weeks) → 900 mg/thrice per day (4 weeks) (oral) | (i) NAC groups presented significant improvements on ABC-irritability subscale |
| [ | Human | 31 in the beginning (NAC 16, placebo 15—3 lost to follow-up, 3 left the trial) (4-12 years) | (i) Doses ranging from 33.6 to 64.3 mg/kg (12 weeks) | (i) GSH level significantly higher in the NAC group ( |